In summary, the present study shows that the inhibition of PDGFRβ alone has no effective influence in CRC cells, but blockade of PDGFRβ, c-KIT and SRC using the small-molecule inhibitor Ki11502 decreases the proliferation capacity of CRC cells, supporting ongoing studies for the implementation of such multitarget treatments in clinical issues. Here, PDGFRB is linked to colorectal carcinoma.